Pharma News

20 December 2024

Dr. Akram Ahmad, Founder of Academically Global, Honored with Times Power Brands North 2024 Award for Excellence in Healthcare Education

Dr. Akram Ahmad, founder of Academically Global, has been recognized with the prestigious Times Power Brands North 2024 Award for Excellence in Healthcare Education. The awards ceremony celebrating leaders and innovators making significant contributions to their industries was held on December 19, 2024, at the Hyatt in Dehradun. Dr. Akram was presented the award by the Honorable Governer of Uttarakhand, Lieutenant General Gurmit Singh (Retd.) for his pioneering work in healthcare education and empowering Indian and global healthcare professionals.

19 December 2024

Zydus receives final approval from USFDA for Lidocaine and Prilocaine Cream USP

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration to manufacture Lidocaine and Prilocaine Cream USP.

19 December 2024

FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease

The U.S. Food and Drug Administration approved Ryoncil remestemcel-L-rknd, an allogeneic donor bone marrow-derived mesenchymal stromal cell therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease SR-aGVHD in pediatric patients 2 months of age and older.

19 December 2024

Granules India Limited announces FDA approval for ADHD Treatment

Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. , has received approval from the U.S. Food & Drug Administration for its Abbreviated New Drug Application for Lisdexamfetamine Dimesylate Chewable Tablets.

19 December 2024

SPARC announces Signing of Binding Letter of Intent with UCSF and Tiller Therapeutics for Pre-clinical Oncology Asset and Associated Intellectual Property

Sun Pharma Advanced Research Company Ltd announced the signing of a binding Letter of Intent with the University of California, San Francisco, through the office of OTMA, and Tiller Therapeutics Inc. to license SPARC’s rights in the joint intellectual property held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LOI outlines the key terms of license and rights for development and commercialization by Tiller.

18 December 2024

New drug shows promise against Duchenne muscular dystrophy

A novel drug holds promise for treating Duchenne muscular dystrophy, a rare genetic disorder that causes severe muscle degeneration. McGill University researchers have discovered that an experimental compound called K884 can boost the natural repair abilities of muscle stem cells. Current treatments can slow muscle damage, but don’t address the root problem.

18 December 2024

UW researchers find previously unknown links between microbial bile acids and the risk of colon cancer

In many ways, that relationship revolves around a specific protein called the farnesoid X receptor, or FXR, which helps maintain a healthy gut through its intimate relationship with bile acids. FXR controls the production of bile acids in the liver, but it also responds in different ways to the presence of various bile acids that microbes have modified.

18 December 2024

Unlocking the Brain : Peptide-Guided Nanoparticles Deliver mRNA to Neurons

Penn Engineers have modified lipid nanoparticles the revolutionary technology behind the COVID-19 mRNA vaccines to not only cross the blood-brain barrier but also to target specific types of cells, including neurons. This breakthrough marks a significant step toward potential next-generation treatments for neurological diseases like Alzheimer’s and Parkinsons.

16 December 2024

Activating the hidden pharmaceutical potential of bacteria

Researchers develop a new genetic method for the production of new active ingredients in bacteria

16 December 2024

Researchers describe a potential target to address a severe heart disease in diabetic patients

Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders. This often under-diagnosed heart function impairment is one of the leading causes of death in diabetic patients and it affects both type 1 and type 2 diabetes. There is no current specific drug treatment or clinical protocol approved to address this disease.

Search

Dr. Akram Ahmad, Founder of Academically Global, Honored with Times Power Brands North 2024 Award for Excellence in Healthcare Education

RECOMMENDED POSTS

Subscribe with us

Jobs by Category